Clinical trials: pMMR/MSS Adenocarcinoma of the Colon or Rectum
Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
Neoadjuvant immunotherapy has shown promising therapeutic effects in mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC).
- Trial name
- BASKETⅢ (NCT06791512)
- Testing
- mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody, mFOLFOX6
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Jun Huang
Solid Tumor, Adult, Refractory Cancer
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT05669430
- Testing
- GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]
- Where
- 13 sites in United States
- Volunteers
- 365 people
- Sponsor
- GV20 Therapeutics
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
MSS, pMMR
Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
The purpose of this study is to evaluate the efficacy and safety of fruquintinib or regorafenib in combination with anti-PD-1 antibody in TKI (fruquintinib or regorafenib)-responded MSS/pMMR metastatic colorectal adenocarcinoma.
- Conditions
- MSS, pMMR, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT04483219
- Testing
- TKI ± anti-PD-1 antibody
- Where
- China
- Volunteers
- 53 people
- Sponsor
- China Medical University, China
MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients
A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer
A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer Main purpose: Evaluate the…
- Trial name
- NCT06936488
- Testing
- Ivonescimab,TAS-102
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Huai'an First People's Hospital
Colorectal Cancer Metastatic, Colon Cancer
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy…
- Conditions
- Colorectal Cancer Metastatic, Colon Cancer, Metastatic Colorectal Cancer, Rectal Cancer
- Trial name
- iRE-C (NCT04108481)
- Testing
- Durvalumab, Yttrium-90 RadioEmbolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Iowa
Rectal Adenocarcinoma
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
To evaluate the efficacy, safety and organ retention rate of short-course radiation combined with Adebrelimab and CAPEOX neoadjuvant therapy in patients with MSS/pMMR ultra low rectal adenocarcinoma.
- Trial name
- NCT06266832
- Testing
- Adebrelimab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sir Run Run Shaw Hospital
PMMR/MSS Adenocarcinoma of the Colon or Rectum, Neoadjuvant Chemoradiotherapy
Study on the Applicability of CCR Criteria in Rectal Cancer
This study aims to explore how well the usual ways of checking if rectal cancer patients are free of disease signs after treatment work for a new treatment method.
- Conditions
- PMMR/MSS Adenocarcinoma of the Colon or Rectum, Neoadjuvant Chemoradiotherapy, Immunotherapy, Complete Response
- Trial name
- NCT06794099
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colon Adenocarcinoma
HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer
The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer.
- Trial name
- NCT06709885
- Testing
- Chidamide + Tislelizumab + chemotherapy (CapeOX ), CapeOX
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University